PharmaVoice Logo

Healthcare Leaders Hub

Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026

PharmaShots

Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026

Shots: Acadia has presented additional data from the P-II (RADIANT) trial of once-daily remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) at CTAD 2026, building on the previously reported topline results At wk.6, the 60 mg dose was favored over placebo on CGI-I-ADP at wks. 2, 4 and 6 (nominal p=0.0232, 0.0082… The post Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026 appeared first on PharmaShots.

Read Full Article
Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors

PharmaShots

Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors

Shots: Ensem Therapeutics has dosed the first patients in its first-in-human P-I/II trial of ETX-929, an oral pan-KRAS inhibitor, in advanced solid tumors with KRAS alterations, including colorectal, pancreatic, NSCLC and gynecologic cancers The open-label, multicenter dose-escalation and expansion study will assess the safety, tolerability, PK, PD and preliminary antitumor activity of ETX-929 as monotherapy… The post Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors appeared first on PharmaShots.

Read Full Article
Pfizer Enters into an Exclusive Licensing Agreement with Starna Therapeutics for In Vivo CAR-T Programs in Autoimmune Diseases

PharmaShots

Pfizer Enters into an Exclusive Licensing Agreement with Starna Therapeutics for In Vivo CAR-T Programs in Autoimmune Diseases

Shots: Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics to develop, manufacture & commercialize 3 pre-IND in vivo CAR-T programs for autoimmune diseases outside Greater China Starna will receive $330M upfront & is eligible for up to $2.3B in development & commercial milestones, plus royalties on net sales; Pfizer will lead clinical… The post Pfizer Enters into an Exclusive Licensing Agreement with Starna Therapeutics for In Vivo CAR-T Programs in Autoimmune Diseases appeared first on PharmaShots.

Read Full Article
nference Enters into a Strategic Collaboration with Novo to Advance Research in Cardiometabolic Disease

PharmaShots

nference Enters into a Strategic Collaboration with Novo to Advance Research in Cardiometabolic Disease

Shots: nference has entered into a strategic collaboration with Novo Nordisk to advance research in cardiometabolic diseases incl. obesity, diabetes & CV disease The collaboration will combine Novo’s clinical trial data with nference’s AI technology & federated healthcare data network to explore treatment effectiveness, safety, disease progression & long-term outcomes, with research programs aimed at… The post nference Enters into a Strategic Collaboration with Novo to Advance Research in Cardiometabolic Disease appeared first on PharmaShots.

Read Full Article
Merck Discontinues the Clinical Development Program of Nemtabrutinib Following P-III (BELLWAVE-011) Data Review

PharmaShots

Merck Discontinues the Clinical Development Program of Nemtabrutinib Following P-III (BELLWAVE-011) Data Review

Shots: Merck has discontinued the P-III (BELLWAVE-011) study of nemtabrutinib (MK-1026) after an external Data Monitoring Committee review suggested that its benefits may not outweigh the risks in the study Following a review of the data in its totality, Merck has also discontinued the broader BELLWAVE program, including the P-III (BELLWAVE-008 & BELLWAVE-010) studies in… The post Merck Discontinues the Clinical Development Program of Nemtabrutinib Following P-III (BELLWAVE-011) Data Review appeared first on PharmaShots.

Read Full Article

Sponsored content

Featured promotional

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

ET Pharma

Nov 18, 2026, 4:02 PM

Merck scraps $2.7 bn Blood cancer buyout nemtabrutinib after risk-return assessment

The US giant acquired nemtabrutinib, a selective BTK inhibitor, under its $2.7 billion takeover of ArQule after paying a hefty 100 per cent premium at $20 per share for the Nasdaq-listed company.

PharmaShots

Nov 18, 2026, 2:52 PM

Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026

Shots: Acadia has presented additional data from the P-II (RADIANT) trial of once-daily remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP) at CTAD 2026, building on the previously reported topline results At wk.6, the 60 mg dose was favored over placebo on CGI-I-ADP at wks. 2, 4 and 6 (nominal p=0.0232, 0.0082… The post Acadia Presents Additional P-II (RADIANT) Study Data of Remlifanserin for Alzheimer’s Disease Psychosis at CTAD 2026 appeared first on PharmaShots.

Pharma Tech

Nov 18, 2026, 2:50 PM

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK’s Nelkarmi will now be in direct competition with Roche’s established ALK inhibitor Alecensa.

PharmaShots

Nov 18, 2026, 2:43 PM

Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors

Shots: Ensem Therapeutics has dosed the first patients in its first-in-human P-I/II trial of ETX-929, an oral pan-KRAS inhibitor, in advanced solid tumors with KRAS alterations, including colorectal, pancreatic, NSCLC and gynecologic cancers The open-label, multicenter dose-escalation and expansion study will assess the safety, tolerability, PK, PD and preliminary antitumor activity of ETX-929 as monotherapy… The post Ensem Therapeutics Doses First Patients in the P-I/II Trial of ETX-929 for KRAS-Altered Advanced Solid Tumors appeared first on PharmaShots.

PharmaShots

Nov 18, 2026, 2:36 PM

Pfizer Enters into an Exclusive Licensing Agreement with Starna Therapeutics for In Vivo CAR-T Programs in Autoimmune Diseases

Shots: Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics to develop, manufacture & commercialize 3 pre-IND in vivo CAR-T programs for autoimmune diseases outside Greater China Starna will receive $330M upfront & is eligible for up to $2.3B in development & commercial milestones, plus royalties on net sales; Pfizer will lead clinical… The post Pfizer Enters into an Exclusive Licensing Agreement with Starna Therapeutics for In Vivo CAR-T Programs in Autoimmune Diseases appeared first on PharmaShots.

PharmaShots

Nov 18, 2026, 2:33 PM

nference Enters into a Strategic Collaboration with Novo to Advance Research in Cardiometabolic Disease

Shots: nference has entered into a strategic collaboration with Novo Nordisk to advance research in cardiometabolic diseases incl. obesity, diabetes & CV disease The collaboration will combine Novo’s clinical trial data with nference’s AI technology & federated healthcare data network to explore treatment effectiveness, safety, disease progression & long-term outcomes, with research programs aimed at… The post nference Enters into a Strategic Collaboration with Novo to Advance Research in Cardiometabolic Disease appeared first on PharmaShots.

News

Latest industry coverage

Google News

Nov 18, 2026, 6:52 PM

Libtayo gets EU approval for six-weekly maintenance dosing - Zenopa

Libtayo gets EU approval for six-weekly maintenance dosing  Zenopa

Google News

Nov 18, 2026, 6:30 PM

Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy? - Zacks Investment Research

Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?  Zacks Investment Research

Google News

Nov 18, 2026, 6:30 PM

European capital markets require efforts to attract biotech listings - Yahoo Finance

European capital markets require efforts to attract biotech listings  Yahoo Finance

Google News

Nov 18, 2026, 6:23 PM

Antimicrobial resistance: Why pension funds matter in AMR - World Economic Forum

Antimicrobial resistance: Why pension funds matter in AMR  World Economic Forum

Google News

Nov 18, 2026, 6:22 PM

Vetter: Building Capacity for a More Complex Injectable Market - Contract Pharma

Vetter: Building Capacity for a More Complex Injectable Market  Contract Pharma

Google News

Nov 18, 2026, 6:17 PM

Amneal Pharmaceuticals stock hits 52-week high at 22.07 USD - Investing.com

Amneal Pharmaceuticals stock hits 52-week high at 22.07 USD  Investing.com

Google News

Nov 18, 2026, 6:06 PM

An Unspoken Rule Spreads Through Biotech: Share Nothing - The New York Times

An Unspoken Rule Spreads Through Biotech: Share Nothing  The New York Times

Google News

Nov 18, 2026, 5:44 PM

BioTech Social Welcomes Former Nasdaq Global Head of Listings Karen Snow to Advisory Board - USA Today

BioTech Social Welcomes Former Nasdaq Global Head of Listings Karen Snow to Advisory Board  USA Today

Google News

Nov 18, 2026, 5:31 PM

What China’s Gene-Editing Deaths Reveal About Its Biotech Industry - Noema Magazine

What China’s Gene-Editing Deaths Reveal About Its Biotech Industry  Noema Magazine

Sponsored placement

Featured promotions

Jeplus.in
Sponsored

Jeplus.in

Purchase All Medicines.Get 10% Offer